building operating infrastructure for drug dev, yet pharma's real bottleneck is trial failure rates, not tooling. does this solve that or just speed up the pipeline?
The benchmark for intelligence is moving faster than most systems are built to handle.
As AI crosses new capability thresholds, the bigger shift is what comes next: intelligence that can act, interact, and operate continuously.
The curve is only part of the story.